Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lyophilized fecal microbiota capsules versus fidaxomicin for recurrent Clostridioides difficile infection
2020-004591-17Phase 3Terminated
- Sponsor
- Mikrobiomik
- Start
- Nov 2020
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Clostridioides difficile infection recurrence (rCDI) comparing MBK-01 with fidaxomicin (2 arms). Primary endpoint: Absence of diarrhea. Started Nov 2020; status: terminated.
02
Drugs
MBK-01fidaxomicin
03
Conditions
Clostridioides difficile infection recurrence (rCDI)
Beyond the preview
Go deeper on 2020-004591-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004591-17.